Fate Therapeutics (FATE) Free Cash Flow (2012 - 2026)
Fate Therapeutics' (FATE) quarterly Free Cash Flow came in at -$31.1 million in Q1 2026, up 9.87% YoY from -$28.3 million in Q1 2025, and down 7.59% on a QoQ basis from -$28.9 million in Q4 2025.
Fate Therapeutics (FATE) Free Cash Flow (2012 - 2026) Analysis & Trends
Fate Therapeutics (FATE) has 15 years of Free Cash Flow data on file, last reported at -$31.1 million in Q1 2026.
- Quarterly Free Cash Flow rose 9.87% year-over-year to -$31.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$108.6 million (up 12.47% YoY) and the FY2025 annual result came in at -$112.0 million, up 8.92% from the prior year.
- Free Cash Flow retreated to -$31.1 million in Q1 2026, from -$28.9 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$23.8 million in Q3 2025 to a low of -$70.0 million in Q2 2022.
- A 5-year average of -$38.5 million and a median of -$32.4 million in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 59.48% in 2022, down 228.52% in 2022.
- Tracing FATE's Free Cash Flow over 5 years: stood at -$47.6 million in 2022, then advanced by 10.37% to -$42.6 million in 2023, then surged by 34.49% to -$27.9 million in 2024, then fell by 3.39% to -$28.9 million in 2025, then slipped by 7.59% to -$31.1 million in 2026.
- The last three Free Cash Flow figures came in at -$31.1 million (Q1 2026), -$28.9 million (Q4 2025), and -$23.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Fate Therapeutics | 298.82 Mn | 298.82 Mn | - | -31.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -31.06 Mn |
| Mar 31, 2026 | -31.06 Mn |
| Dec 31, 2025 | -28.87 Mn |
| Dec 31, 2025 | -28.87 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Sep 30, 2025 | -23.78 Mn |
| Jun 30, 2025 | -24.93 Mn |
| Jun 30, 2025 | -24.93 Mn |
| Mar 31, 2025 | -34.46 Mn |
| Mar 31, 2025 | -34.46 Mn |
| Dec 31, 2024 | -27.92 Mn |
| Dec 31, 2024 | -27.92 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Sep 30, 2024 | -29.30 Mn |
| Jun 30, 2024 | -32.43 Mn |
| Jun 30, 2024 | -32.43 Mn |
| Mar 31, 2024 | -33.36 Mn |
| Mar 31, 2024 | -33.36 Mn |
| Dec 31, 2023 | -42.62 Mn |
| Dec 31, 2023 | -42.62 Mn |